A share price of Cellectis ADR [CLLS] is currently trading at $2.13, up 27.16%. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The CLLS shares have gain 51.06% over the last week, with a monthly amount glided 12.70%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Cellectis ADR [NASDAQ: CLLS] stock has seen the most recent analyst activity on March 17, 2023, when Bryan Garnier initiated its Buy rating and assigned the stock a price target of $6. Previously, Robert W. Baird upgraded its rating to Outperform on May 18, 2022, and kept the price target unchanged to $10. On January 06, 2022, downgrade downgraded it’s rating to Equal Weight and revised its price target to $16 on the stock. JMP Securities started tracking the stock assigning a Mkt Outperform rating and suggested a price target of $20 on November 30, 2021. William Blair downgraded its rating to a Mkt Perform. Robert W. Baird downgraded its rating to Neutral for this stock on October 08, 2021, and downed its price target to $10. In a note dated April 28, 2021, Guggenheim downgraded an Neutral rating on this stock.
Cellectis ADR experienced fluctuations in its stock price throughout the past year between $1.41 and $3.38. Cellectis ADR [NASDAQ: CLLS] shares were valued at $2.13 at the most recent close of the market.
Analyzing the CLLS fundamentals
Trailing Twelve Months sales for Cellectis ADR [NASDAQ:CLLS] were 29.07M which represents 10351.61% growth. Gross Profit Margin for this corporation currently stands at 1.04% with Operating Profit Margin at -2.71%, Pretax Profit Margin comes in at -3.67%, and Net Profit Margin reading is -2.94%. To continue investigating profitability, this company’s Return on Assets is posted at -0.22, Equity is -0.75 and Total Capital is -0.34. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.36.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 1.8500 points at the first support level, and at 1.5700 for the second support level. However, for the 1st resistance point, the stock is sitting at 2.3200, and for the 2nd resistance point, it is at 2.5100.
Ratios To Look Out For
To put it in perspective, the Current Ratio for Cellectis ADR [NASDAQ:CLLS] is 1.78. As well, the Quick Ratio is 1.78, while the Cash Ratio is 0.96. Considering the valuation of this stock, the price to sales ratio is 5.28, the price to book ratio is 1.65.
